Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short term Debt: 2019-2022

Historic Short term Debt for Theravance Biopharma (TBPH) over the last 2 years, with Mar 2022 value amounting to $9.0 million.

  • Theravance Biopharma's Short term Debt fell 22.70% to $9.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $9.0 million, marking a year-over-year decrease of 22.70%. This contributed to the annual value of $16.9 million for FY2021, which is 12.38% down from last year.
  • According to the latest figures from Q1 2022, Theravance Biopharma's Short term Debt is $9.0 million, which was down 46.80% from $16.9 million recorded in Q4 2021.
  • Over the past 5 years, Theravance Biopharma's Short term Debt peaked at $19.3 million during Q4 2020, and registered a low of $6.9 million during Q2 2021.
  • Over the past 3 years, Theravance Biopharma's median Short term Debt value was $12.1 million (recorded in 2021), while the average stood at $12.7 million.
  • Per our database at Business Quant, Theravance Biopharma's Short term Debt soared by 96.26% in 2020 and then declined by 22.70% in 2022.
  • Theravance Biopharma's Short term Debt (Quarterly) stood at $9.9 million in 2019, then surged by 96.26% to $19.3 million in 2020, then dropped by 12.38% to $16.9 million in 2021, then declined by 22.70% to $9.0 million in 2022.
  • Its last three reported values are $9.0 million in Q1 2022, $16.9 million for Q4 2021, and $12.5 million during Q3 2021.